ATLANTA, Feb. 2, 2012 /PRNewswire/ -- CryoLife, Inc.
(NYSE: CRY), a leading tissue processing and medical device Company
focused on cardiac and vascular surgery, announced today that 2011
fourth quarter and year end financial results will be released on
Thursday, February 16, 2012. On
that day, the Company will hold a teleconference call and live
webcast at 10:00 a.m. Eastern Time to
discuss the results, followed by a question and answer session
hosted by Steven G. Anderson,
president and chief executive officer of CryoLife, Inc.
To listen to the live teleconference, please dial 201-689-8261 a
few minutes prior to 10:00 a.m. A replay of the
teleconference will be available February 16
through February 23 and can be accessed by calling (toll
free) 877-660-6853 or 201-612-7415. The account number for
the replay is 244 and the conference number is 388168.
The live webcast and replay can be accessed by going to the
Investor Relations section of the CryoLife website at
www.cryolife.com and selecting the heading Webcasts &
Presentations.
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing
and distribution of implantable living human tissues for use in
cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG pulmonary
heart valve, processed using CryoLife's proprietary SynerGraft®
technology, has FDA 510(k) clearance for the replacement of
diseased, damaged, malformed, or malfunctioning native or
prosthetic pulmonary valves. CryoLife's CryoPatch® SG
pulmonary cardiac patch has FDA 510(k) clearance for the repair or
reconstruction of the right ventricular outflow tract (RVOT), which
is a surgery commonly performed in children with congenital heart
defects, such as Tetralogy of Fallot, Truncus Arteriosus, and
Pulmonary Atresia. CryoPatch SG is distributed in three anatomic
configurations: pulmonary hemi-artery, pulmonary trunk, and
pulmonary branch. CryoLife's BioGlue® Surgical Adhesive is
FDA approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels. BioGlue is
also CE marked in the European Community and approved in
Canada and Australia for use in soft tissue repair and
was recently approved in Japan for
use in the repair of aortic dissections. CryoLife, through
its subsidiary Cardiogenesis Corporation, specializes in the
treatment of cardiovascular disease and the sale of devices that
treat severe angina. Its market leading FDA-approved Holmium:
YAG laser system and single use fiber-optic delivery systems are
used to perform a surgical procedure known as Transmyocardial
Revascularization (TMR). CryoLife distributes PerClot®, an
absorbable powder hemostat, in the European Community.
CryoLife's BioFoam™ Surgical Matrix is CE marked in the European
Community for use as an adjunct in the sealing of abdominal
parenchymal tissues (liver and spleen) when cessation of bleeding
by ligature or other conventional methods is ineffective or
impractical.
For additional information about the company, visit CryoLife's
website: http://www.cryolife.com.
Contacts:
|
|
|
|
CryoLife
|
The
Ruth Group
|
D. Ashley
Lee
|
Nick
Laudico / Zack Kubow
|
Executive
Vice President, Chief Financial Officer
|
646-536-7030 / 7020
|
and Chief
Operating Officer
|
nlaudico@theruthgroup.com
|
Phone:
770-419-3355
|
zkubow@theruthgroup.com
|
SOURCE CryoLife, Inc.